Shots:
- Alvotech and Advanz Pharma have submitted a European regulatory application for AVT29, a biosimilar version of Eylea 8 mg (aflibercept 114.3 mg/mL), marketed as Eylea HD in the US
- The application was submitted as a line extension to Mynzepli (AVT06), a biosimilar version to Eylea 2mg, which received EC approval in Aug 2025 in vial & PFS presentations for various retinal diseases
- Eylea 8 mg treats retinal diseases with longer dosing intervals of 16wks. for eligible pts, compared with 8wks. for the 2 mg formulation, potentially reducing maintenance injections & easing treatment burden
Ref: Globenewswire | Image: Alvotech & Advanz | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
